These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 12352068)
1. Prophylactic granulocyte colony-stimulating factor in the critically ill: carefully balancing the benefits and risks. Quezado ZM; Eichacker PQ Crit Care Med; 2002 Sep; 30(9):2162-4. PubMed ID: 12352068 [No Abstract] [Full Text] [Related]
2. Prophylactic granulocyte colony-stimulating factor in critically ill patients: not time yet. Esposito C; Banks SM; Eichacker PQ Crit Care Med; 1998 Apr; 26(4):636-7. PubMed ID: 9559595 [No Abstract] [Full Text] [Related]
3. Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Weiss M; Moldawer LL; Schneider EM Blood; 1999 Jan; 93(2):425-39. PubMed ID: 9885204 [No Abstract] [Full Text] [Related]
4. Granulocyte colony-stimulating factor as the expecting sword for the treatment of severe sepsis. Murata A Curr Pharm Des; 2003; 9(14):1115-20. PubMed ID: 12769751 [TBL] [Abstract][Full Text] [Related]
5. Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission. Weiss M; Voglic S; Harms-Schirra B; Lorenz I; Lasch B; Dumon K; Gross-Weege W; Schneider EM Intensive Care Med; 2003 Jun; 29(6):904-914. PubMed ID: 12682721 [TBL] [Abstract][Full Text] [Related]
6. The use of granulocyte colony-stimulating factor in critically ill patients. van der Poll T Crit Care Med; 2000 Nov; 28(11):3758-9. PubMed ID: 11098990 [No Abstract] [Full Text] [Related]
7. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: double-edged swords. Wilson RF; Henry TD J Am Coll Cardiol; 2005 Nov; 46(9):1649-50. PubMed ID: 16256863 [No Abstract] [Full Text] [Related]
8. Colony-stimulating factor use in the context of refined risk and benefit assessments. Crawford J Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):9-10. PubMed ID: 16736982 [No Abstract] [Full Text] [Related]
9. Use of granulocyte colony-stimulating factor in patients with severe sepsis or septic shock. Mohammad RA Am J Health Syst Pharm; 2010 Aug; 67(15):1238-45. PubMed ID: 20651313 [TBL] [Abstract][Full Text] [Related]
11. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections in nonneutropenic patients. Root RK; Dale DC J Infect Dis; 1999 Mar; 179 Suppl 2():S342-52. PubMed ID: 10081506 [TBL] [Abstract][Full Text] [Related]
18. Sweet syndrome associated with granulocyte colony-stimulating factor. Bidyasar S; Montoya M; Suleman K; Markowitz AB J Clin Oncol; 2008 Sep; 26(26):4355-6. PubMed ID: 18779624 [No Abstract] [Full Text] [Related]
19. [Advances in the research of clinical use of recombinant human granulocyte colony-stimulating factors]. Jiang FG; Geng JP; Yang CL Zhonghua Nei Ke Za Zhi; 1991 Nov; 30(11):723-5. PubMed ID: 1726145 [No Abstract] [Full Text] [Related]